BURLINGTON, Ontario – May 29, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces its collaboration in the National Football League (NFL) – funded clinical trial program entitled “Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in Contact Sports” led by Dr. J. Patrick Neary and researchers at the University of Regina.

RDT will partake in a randomized, two-arm clinical study, which is part of a larger clinical program designed by an expert team of cerebrovascular and neuro-physiologists, clinical psychologists, pharmacokineticists, and physicians from the Universities of Regina, Saskatchewan, and British Columbia.

The primary research objective of the study is to determine the relative oral bioavailability and other pharmacokinetic (PK) parameters of the non-psychoactive cannabidiol (CBD) and its metabolites, when administered to a healthy young adult population as RDT’s sublingual QuickStrip™ product, versus a standard oral formulation.

The data generated from this study will demonstrate the efficacy of the QuickStrip™ product and serve as the basis for including RDT’s QuickStrip™ in the subsequent clinical studies as part of the overall clinical program funded by the NFL.

“This study has the potential to change not only the lives of current and former NFL players, but also the lives of anyone who may suffer from a concussion,” said Dr. Patrick Neary, exercise physiologist and professor in the Faculty of Kinesiology and Health Studies at the University of Regina.

About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid–dose.com.

Contacts:
RDT Investor Contact:
Mark Upsdell, CEO
[email protected]
416-477-1052

 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions, or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.  This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the Common Shared States. The securities described in this news release have not been and will not be registered under the Common Shared States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the Common Shared States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.